Mylan Inc. has appointed Roger Graham as president of Mylan Specialty.


Mylan, Roger Graham, Mylan Specialty, Advandx, Tony Mauro, Heather Bresch, pharmaceutical firms






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan names chief of specialty business

June 24th, 2013

PITTSBURGH – Mylan Inc. has appointed Roger Graham as president of Mylan Specialty.

Mylan said Monday that Graham joins the company from Advandx, a private developer of in-vitro diagnostic tests in the infectious disease space.

Graham will report to Tony Mauro, president of Mylan North America.

"Roger's deep brand pharmaceutical industry experience, entrepreneurial mind-set and goal-oriented leadership make him the ideal candidate to lead Mylan Specialty as we continue to expand this important business," stated Mylan chief executive officer Heather Bresch. "We remain very excited about the growth prospects of the specialty business and are confident that Roger will bring immediate value to our entire North American organization and help accelerate achievement of our ambitions for Mylan Specialty."

At Advandx, Graham was chief commercial officer and developed the company's growth strategy for the U.S. and European markets. Before that, he spent nearly a decade in executive-level marketing and sales positions at three branded pharmaceutical firms: Auxilium Pharmaceuticals, Adolor Corp. and Yamanouchi Pharma America, where he established, rebuilt and/or expanded U.S. commercial operations, according to Mylan.

Earlier, Graham worked at Ortho McNeil, a division of Johnson & Johnson, where he was vice president of the company's $2 billion anti-infective, analgesia and urology franchise, and its 2,300 primary care and hospital sales and marketing associates. Graham also built Ortho McNeil's $500 million neuroscience and metabolic franchise via the launch and life-cycle development of Topamax, Mylan said.

Also, Graham served as director of marketing for Roche's CNS, pain and dermatology franchises. He began his career at Schering-Plough and, over nearly a decade, took on positions of increasing responsibility in the company's allergy, respiratory and oncology sales and marketing organizations, Mylan reported.

Advertisement